Journals / Interdisciplinary Medical Journal / 2023 / Cilt: 14 Sayı: 48

Breast cancer and the molecular mechanism of estrogen signaling

Pages
57–68
Publication Date
2023-04-30
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This review summarizes the pathology of breast cancer, estrogenic compounds, estrogen receptors, genomic and non-genomic molecular signaling mechanisms mediated by estrogen and estrogen receptor.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Cancer is a complex pathology that occurs due to the uncontrolled proliferation and growth of cells in any organ or tissue of the body.
📊
Key Findings & Data:The most significant limitation to the success of the treatment approaches developing drug resistance in breast cancer cells, and the disease relapses after a certain period and exhibits a more aggressive profile.
💡
Conclusion & Impact:This review summarizes the pathology of breast cancer, estrogenic compounds, estrogen receptors, genomic and non-genomic molecular signaling mechanisms mediated by estrogen and estrogen receptor.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Breast Cancer · Estrogen · Estrogen Receptor

Abstract

Cancer is a complex pathology that occurs due to the uncontrolled proliferation and growth of cells in any organ or tissue of the body. Breast cancer is the most frequently diagnosed cancer among women worldwide and is the second leading cause of cancer-related deaths. Breast cancer is a pathology that exhibits heterogeneity in which genetic and environmental risk factors play a role. Although many treatment approaches have been developed for breast cancer today, the frequency of the number of patients diagnosed with breast cancer and lost their lives due to this reason is increasing in the world. The most significant limitation to the success of the treatment approaches developing drug resistance in breast cancer cells, and the disease relapses after a certain period and exhibits a more aggressive profile. Therefore, understanding the molecular biology of breast cancer is essential for developing potent therapeutic approaches. It is known that the development of breast cancer is related to changes in direct and indirect signaling mechanisms mediated by estrogen and estrogen receptor. These signaling mechanisms exhibit highly complex interaction patterns. This review summarizes the pathology of breast cancer, estrogenic compounds, estrogen receptors, genomic and non-genomic molecular signaling mechanisms mediated by estrogen and estrogen receptor.

🔖

Cite This Article

ERZURUMLU, Y., DOĞAN, H. K. (2023). Breast cancer and the molecular mechanism of estrogen signaling. Interdisciplinary Medical Journal, Cilt: 14 Sayı: 48, 57–68. https://ajindex.com/articles/931524

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Rivenbark AG, O’Connor SM, Coleman WB. Molecular and cellular heterogeneity in breast cancer: challenges for personalized medicine. Am J Pathol. 2013;183(4):1113-1124. DOI: https://doi.org/10.1016/j.ajpath.2013.08.002
  2. Hong R, Ma F, Xu B, Li Q, Zhang P, Yuan P et al. Efficacy of platinum-based chemotherapy in triple-negative breast cancer patients with metastases confined to the lungs: a single-institute experience. Anti-Cancer Drugs. 2014 Oct;25(9):1089-94. DOI: https://doi.org/10.1097/CAD.0000000000000138 Akkaş Gürsoy A. Meme kanserinde eğitimcinin eğitimi programı II kitapçığı, Trabzon. 2005. Aydıntuğ S. Meme kanserinde erken tanı. STED. 2004 Jun;13(6):226-229.
  3. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics. CA Cancer J Clin. 2023;73(1):17-48. DOI: https://doi.org/10.3322/caac.21763
  4. Gültekin M, Boztaş G, Utku EŞ, Ergün AK, Sevinç A, Tütüncü S ve ark. Türkiye kanser istatistikleri. Sağlık Bakanlığı, Türkiye Halk Sağlığı Kurumu, 2014 Ocak;43:12-32.
  5. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global Cancer Statistics 2018: GLOBOCAN estimates of ıncidence and mortality worldwide for 36 cancers in 185 countries. CA:Cancer J Clın. 2018;394–424. DOI: https://doi.org/10.3322/caac.21492
  6. Assi HA, Khoury KE, Dbouk H, Khalil LE, Mouhieddine TH, El Saghir NS. Epidemiology and prognosis of breast cancer in young women. J Thorac Dis. 2013 Jun;5(1):2–8. DOI: https://doi.org/10.3978/j.issn.2072-1439.2013.05.24
  7. Oeffinger KC, Fontham ET, Etzioni R, Herzig A, Michaelson JS, Shih YC et al. Breast cancer screening for women at average risk: 2015 guideline update from the American Cancer Society. JAMA. 2015 Oct 20;314(15):1599-614. DOI: https://doi.org/10.1001/jama.2015.12783 Somunoğlu S. Meme kanseri: belirtileri ve erken tanıda kullanılan tarama yöntemleri. Fırat Sağlık Hizmetleri Dergisi, 2009;4(10), 103-122.
  8. Koçak S, Çelik L, Özbaş S, Saka DS, Tükün A, Yalçın B. Meme kanserinde risk faktörleri, riskin değerlendirilmesi ve prevansiyon: İstanbul 2010 konsensus raporu. J Breast Health. 2011;7(2):47-67.
  9. Fitzgibbons PL, Page DL, Weaver D, Thor AD, Allred DC, Clark GM et al. Prognostic factors in breast cancer: College of American Pathologists consensus statement 1999. Arch Pathol Lab Med. 2000;124(7):966-78. DOI: https://doi.org/10.5858/2000-124-0966-PFIBC
  10. Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI et al. Revision of the American Joint Committee on cancer staging system for breast cancer. J Clin Oncol. 2002 Sep;20(17):3628-